{"classes":[{"categories":[{"measurements":[{"comment":"Summary statistics are not presented if Number of observations Above Lower limit of Quantification (NALQ) = 0 or more than 50% of the concentration data were missing at a particular time point.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 0 Day1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18","value":"4.267"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28","value":"8.326"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day8: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34","value":"12.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day15: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27","value":"13.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43","value":"16.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day8: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45","value":"17.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day15: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49","value":"19.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 3 Day1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35","value":"21.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 4 Day1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43","value":"21.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 5 Day1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34","value":"23.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 6 Day1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"87","value":"18.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 7 Day1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51","value":"24.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 8 Day1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41","value":"21.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 12 Day1: Predose"},{"categories":[{"measurements":[{"comment":"Summary statistics are not presented if NALQ = 0 or more than 50% of the concentration data were missing at a particular time point.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 16 Day1: Predose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic concentration population was defined as all enrolled participants who were treated and had at least 1 analyte concentration. Here, 'Number Analyzed' signifies participants evaluable at specific timepoints.","reportingStatus":"POSTED","timeFrame":"At pre-dose on Day 1 of Cycle 0, 3, 4, 5, 6, 7, 8, 12, 16; at pre-dose on Days 1, 8, 15 of Cycle 1 and 2","title":"Pre-dose Trough Serum Concentrations After Multiple Doses of Elranatamab","type":"SECONDARY","unitOfMeasure":"Microgram per milliliter"}